Breaking News

Shooting Reported at High School Near Seattle
Tweet TWEET

Ablynx: PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR

Ablynx: PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY
2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION

GHENT, Belgium, 30 October 2013 -Ablynx [Euronext Brussels: ABLX] today
announced, in accordance with Article 14 of the Belgian Law of 2 May 2007
regarding the publication of major shareholdings in issuers whose securities
are admitted to trading on a regulated market (the "Transparency Law"), that
it received a notification of shareholdings from Aviva plc and Aviva Investors
Global Services Limited.

The above shareholders notified that they  have exceeded the 3% threshold  and 
now hold  1,482,342  Ablynx  shares,  which represent  3.04%  of  the  current 
48,827,646 outstanding shares of Ablynx.

The voting  rights  are  managed  and controlled  by  Aviva  Investors  Global 
Services Limited, with the following  chain of controlled undertakings:  Aviva 
plc (Parent Company), Aviva Group Holdings Limited (wholly owned subsidiary of
Aviva plc), Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva
Group Holdings Limited), Aviva Investors Global Services Limited (wholly owned
subsidiary of Aviva Investors Holdings Limited).

Full versions of all transparency  notifications are available on the  website 
of Ablynx, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies^®, a novel class of therapeutic proteins based on  single-domain 
antibody  fragments,  for  a  range  of  serious  human  diseases,   including 
inflammation, haematology, oncology and pulmonary disease. Today, the  Company 
has approximately  25  programmes in  the  pipeline and  seven  Nanobodies  at 
clinical development stage.  Ablynx has on-going  research collaborations  and 
significant partnerships with major pharmaceutical companies including AbbVie,
Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis.  The 
Company is headquartered in Ghent, Belgium.  More information can be found  on 
www.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
 +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
e: ablynx@consilium-comms.com

press release in pdf format

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Ablynx via Thomson Reuters ONE
HUG#1739362
 
Press spacebar to pause and continue. Press esc to stop.